GPC1 and neoplasm: The development of nanotechnology approaches loaded with anticancer drugs (e.g., doxorubicin, paclitaxel) that can penetrate exclusively into the tumor thanks to active targeting mechanisms, such as conjugation with mAbs that recognize the GPC1, expressed mainly on the surface of malignant cells, would allow for focusing the toxicity exclusively to the tumor limiting the toxicity on healthy tissues and the development of resistance.